ClinicalTrials.gg

Program

MAR001

A development code.

Its studies are mostly in Hypertriglyceridemia, led by Marea Therapeutics.

Furthest: phase 2, since May 31, 20233 company-led studies, 2 open or runningNext primary completion: Nov 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Marea Therapeutics32 open or runningphase 2since May 31, 2023May 31, 2023Nov 2027phase 2 · NCT07028749

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2023First study: phase 2 study in HypertriglyceridemiaFirst studyNCT05896254 · 55 enrolled · Australia
  2. Jun 11, 2025Phase 2 study in HypertriglyceridemiaNCT07028749 · 316 planned · United States, Australia, Canada and more
  3. Sep 22, 2025Phase 2 study in HypertriglyceridemiaNCT07199309 · 30 planned · United States

Ahead

  1. Nov 2027Primary completion: phase 2 study in HypertriglyceridemiaNCT07028749

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07199309Hypertriglyceridemia · United States2RecruitingJul 202630
NCT07028749Hypertriglyceridemia · United States, Australia, Canada and more2RecruitingNov 2027316
NCT05896254Hypertriglyceridemia · Australia2CompletedDec 13, 202455

How it is read

Names in the registry

  • “MAR001”, 3 entries

Codes read as this program: MAR001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.